Amicus Therapeutics Book Value 2011-2026 | FOLD

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Amicus Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
194 M	160 M	123 M	307 M	286 M	476 M	343 M	353 M	-	348 M	122 M	45.8 M	69.2 M	29.6 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
476 M	29.6 M	220 M

Quarterly Book Value Amicus Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
230 M	204 M	194 M	194 M	179 M	133 M	-	160 M	133 M	112 M	103 M	123 M	133 M	-	239 M	307 M	377 M	214 M	251 M	286 M	286 M	286 M	286 M	476 M	476 M	476 M	476 M	343 M	343 M	343 M	343 M	353 M	353 M	353 M	353 M	1.04 B	1.04 B	1.04 B	1.04 B	908 M	908 M	908 M	908 M	210 M	210 M	210 M	210 M	128 M	128 M	128 M	128 M	110 M	110 M	110 M	110 M	69.8 M	69.8 M	69.8 M	69.8 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.04 B	69.8 M	333 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	50.5 M	$ 1.65	7.91 %	$ 92.9 M	China
AstraZeneca PLC AZN	40.9 B	$ 93.52	-1.2 %	$ 96.9 B	Britain
Autolus Therapeutics plc AUTL	427 M	$ 1.52	-16.3 %	$ 388 M	Britain
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.59	1.99 %	$ 8.64 B	Australia
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Biogen BIIB	16.7 B	$ 184.48	-1.67 %	$ 26.9 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
BioNTech SE BNTX	19.4 B	$ 102.17	2.32 %	$ 27.2 B	Germany
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 4.25	1.67 %	$ 9.25 B	Israel
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-106 M	$ 207.49	2.22 %	$ 5 B	Danmark
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Catalyst Biosciences CBIO	78.5 M	$ 10.84	0.46 %	$ 714 M	USA
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
Corcept Therapeutics Incorporated CORT	680 M	$ 37.35	-0.4 %	$ 3.86 B	USA
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Catalyst Pharmaceuticals CPRX	728 M	$ 23.18	2.02 %	$ 2.75 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Celldex Therapeutics CLDX	747 M	$ 25.59	-6.54 %	$ 1.65 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Cellectis S.A. CLLS	131 M	$ 4.22	-4.2 %	$ 116 M	France
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	732 M	$ 29.43	6.09 %	$ 1.43 B	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	1.66 B	$ 9.66	2.28 %	$ 1.53 B	Britain
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 66.05	2.3 %	$ 8.83 B	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Crinetics Pharmaceuticals CRNX	1.32 B	$ 55.11	3.49 %	$ 4.45 B	USA
Abeona Therapeutics ABEO	14.8 M	$ 5.14	-1.06 %	$ 110 M	USA
CRISPR Therapeutics AG CRSP	1.93 B	$ 55.17	2.47 %	$ 4.65 B	Schweiz
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	2.33 B	$ 632.29	0.09 %	$ 47.9 B	USA
ADiTx Therapeutics ADTX	8.29 M	$ 0.81	1.96 %	$ 10.7 K	USA
Aytu BioScience AYTU	124 M	$ 2.7	2.27 %	$ 17 M	USA